Using cutting-edge in-silico technologies to design molecules of all modalities – small molecules, peptides, antibodies, enzymes, proteins, and nucleotides.
“Raven biosciences are collaborative, insightful, and always focused on creating solutions that maximize customer value. With their unique combination of deep insights into AI, in-silico methods, and medicinal chemistry they have provided great value to several of our portfolio companies.“
Peter Horn Møller, Chief Investment Officer and Founding Partner, Marigold Investment Management
“We have partnered with Raven Biosciences on multiple occasions to support our drug development programs through their drug design expertise. We’re proud to work with a team that shares our passion for driving innovation in drug discovery.“
Victor Bustos, Co-founder and CEO, Refoxy Pharmaceuticals
“We used Raven biosciences’ EpiC platform to accurately identify and characterize the epitope of our phase 3 ready antibody, mitazalimab.
In contrast to other methods, EpiC gave us new critical insights that allowed us to identify novel CD40 antibodies with similar binding characteristics, enabling the development of the next generation of conditional CD40 agonists.”
Søren Bregenholt, CEO, Alligator bioscience
“ChemX makes it super easy to wrangle your data and test out different approaches to training machine learning models in order to train the best model. Using the models for screening is straight forward and the explainability analyses help to understand what the model learned of the structure/activity relationship.”
